Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 14/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 14/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22049611 | 0.88 | OPRM1 (0.34) | UBE2MDCUN1D1ALDH1A1TDP1OPRM1 | |
| SCHEMBL22332273 | 0.85 | CYP2D6 (0.41) | UBE2MDCUN1D1OPRM1OPRL1 | |
| SCHEMBL23168917 | 0.80 | CYP2D6 (0.37) | UBE2MDCUN1D1OPRM1OPRL1 | |
| SCHEMBL14804459 | 0.77 | HRH3 (0.46) | ALDH1A1TDP1 | |
| SCHEMBL19040733 | 0.76 | UBE2M (0.31) | UBE2MDCUN1D1 | |
| SCHEMBL25533682 | 0.76 | UBE2M (0.38) | UBE2MDCUN1D1 | |
| SCHEMBL25090277 | 0.75 | OPRM1 (0.36) | UBE2MDCUN1D1OPRM1OPRL1 | |
| SCHEMBL25447572 | 0.75 | SIGMAR1 (0.46) | UBE2MDCUN1D1ALDH1A1OPRM1OPRL1 | |
| SCHEMBL11573468 | 0.73 | — | — | |
| SCHEMBL19630484 | 0.73 | KDM4E (0.38) | UBE2MDCUN1D1OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062760-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062760-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPRJ, PTPRC | UBE2M 3757/4885DCUN1D1 2850/4885ALDH1A1 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.